New pill takes on rare salivary gland and colon cancers
NCT ID NCT06462183
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have measurable disease that has progressed after prior therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RGT-61159 (an oral MYB inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced adenoid cystic carcinoma or colorectal cancer that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 105 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Next Oncology VA
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ottawa Hospital Cancer Centre
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States